title: [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].
abstract: Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis. Relationships between self-evaluation parameters and personal features, psychopathological and psychophysiological parameters of patients, drug action characteristics, and course treatment effectiveness have been analyzed. Results suggest that the self-rated high tolerability of ladasten treatment is comparable with that of placebo. No relationships are found between the self-evaluated single-dose effects of ladasten and personal features of patients. Correlations of the self-estimations and some psychopathological and psychophysiological parameters before treatment, main drug effects, and overall course treatment effectiveness are revealed, whereas the self-evaluation of placebo effect was related to personal features.
authors.forename: M A
authors.initials: MA
authors.lastname: Reutova
authors.forename: S A
authors.initials: SA
authors.lastname: Siuniakov
authors.forename: T S
authors.initials: TS
authors.lastname: Siuniakov
authors.forename: O A
authors.initials: OA
authors.lastname: Dorofeeva
authors.forename: L É
authors.initials: LÉ
authors.lastname: Mametova
authors.forename: G G
authors.initials: GG
authors.lastname: Neznamov
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000339:Affect / Q000187:drug effects*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D059026:Diagnostic Self Evaluation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects*; D009440:Neurasthenia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010808:Physical Examination; D015990:Placebo Effect; D011603:Psychophysiology; D012107:Research Design; D007319:Sleep Initiation and Maintenance Disorders; D012894:Sleep Stages; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; C493151:N-(2-adamantyl)-N-p-bromophenylamine; D000218:Adamantane